International Journal of Hepatology / 2011 / Article / Tab 3

Review Article

Treatment of Hepatitis B in Decompensated Liver Cirrhosis

Table 3

Antiviral Agents with Activity against Wild Type and Lamivudine resistant HBV.

AgentDaily doseSide effectsComments

Adefovir10 mgDose-dependant nephrotoxicityDrug resistance after 12 months
Entecavir1 mgNo major side effects to dateDrug resistance eventually in lamivudine-resistant mutants
Tenofovir300 mgNeuropathy, nausea, CPK elevations, Fanconi syndromeNo drug resistance up to 4 years

We are committed to sharing findings related to COVID-19 as quickly as possible. We will be providing unlimited waivers of publication charges for accepted research articles as well as case reports and case series related to COVID-19. Review articles are excluded from this waiver policy. Sign up here as a reviewer to help fast-track new submissions.